{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "FlublokPI",
  "verification_stats": {
    "total_extracted": 2,
    "verified": 2,
    "rejected": 0,
    "verification_rate": 1.0
  },
  "verified_evidence": [
    {
      "id": "comp_1",
      "quote": "The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 \u2013 [Attack rate Flublok Quadrivalent Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5).",
      "supports_claim": true,
      "explanation": "The quote appears almost verbatim on page 4: 'The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 \u2013 [Attack rate Flublok Quadrivalent Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5).' The only minor difference is the formatting of 'Quadrivalent' and spacing, but the content is the same.. The quote directly describes Study 6, which evaluated Flublok Quadrivalent against a 'Comparator.' Elsewhere in the document (page 3), it is specified that the Comparator in Study 6 is Fluarix Quadrivalent (manufactured by GlaxoSmithKline), a standard-dose quadrivalent influenza vaccine. Therefore, the quote genuinely supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "presence_explanation": "The quote appears almost verbatim on page 4: 'The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 \u2013 [Attack rate Flublok Quadrivalent Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5).' The only minor difference is the formatting of 'Quadrivalent' and spacing, but the content is the same.",
      "support_explanation": "The quote directly describes Study 6, which evaluated Flublok Quadrivalent against a 'Comparator.' Elsewhere in the document (page 3), it is specified that the Comparator in Study 6 is Fluarix Quadrivalent (manufactured by GlaxoSmithKline), a standard-dose quadrivalent influenza vaccine. Therefore, the quote genuinely supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "original_relevance": "This quote directly references the comparison of Flublok Quadrivalent to a 'Comparator' in Study 6, supporting that Flublok Quadrivalent was evaluated against another quadrivalent vaccine in a pivotal trial."
    },
    {
      "id": "comp_2",
      "quote": "Abbreviations: rtPCR=reversetranscriptasepolymerasechainreaction; Comparator=U.S.- licensed quadrivalent inactivated influenza vaccine, Fluarix quadrivalent, manufactured by Glaxo smith kline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100].",
      "supports_claim": true,
      "explanation": "A very similar version of the quote appears on page 4 of the document: 'Abbreviations: rtPCR=reversetranscriptasepolymerasechainreaction; Comparator=U.S.- licensed quad rival ent in activated influenza vaccine, Fluarix quad rival ent, manufactured by Glaxo smith kline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100].' The wording and abbreviations match the quote to verify, with only minor differences in spacing and line breaks.. The quote directly states that the 'Comparator' in the pivotal trial was 'U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix quadrivalent, manufactured by GlaxoSmithKline.' This confirms that Flublok (quadrivalent) was evaluated in a head-to-head trial against Fluarix (quadrivalent standard-dose vaccine), as the claim asserts.",
      "presence_explanation": "A very similar version of the quote appears on page 4 of the document: 'Abbreviations: rtPCR=reversetranscriptasepolymerasechainreaction; Comparator=U.S.- licensed quad rival ent in activated influenza vaccine, Fluarix quad rival ent, manufactured by Glaxo smith kline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100].' The wording and abbreviations match the quote to verify, with only minor differences in spacing and line breaks.",
      "support_explanation": "The quote directly states that the 'Comparator' in the pivotal trial was 'U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix quadrivalent, manufactured by GlaxoSmithKline.' This confirms that Flublok (quadrivalent) was evaluated in a head-to-head trial against Fluarix (quadrivalent standard-dose vaccine), as the claim asserts.",
      "original_relevance": "This quote clarifies that the 'Comparator' used in the pivotal trial was specifically Fluarix quadrivalent, confirming the head-to-head evaluation of Flublok Quadrivalent against Fluarix Quadrivalent."
    }
  ],
  "rejected_evidence": [],
  "model_used": "gpt-4.1"
}